{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:45:04Z","timestamp":1791362704588,"version":"4.3.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Southern and Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2020011"],"award-info":[{"award-number":["2020011"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to evaluate the efficacy of opportunistic treatment of hepatitis C virus (HCV) infection among hospitalized people who inject drugs (PWID).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a pragmatic, stepped wedge cluster randomized trial recruiting HCV RNA positive individuals admitted for inpatient care in departments of internal medicine, addiction medicine, and psychiatry at three hospitals in Oslo, Norway. Seven departments were sequentially randomized to change from control conditions (standard of care referral to outpatient care) to intervention conditions (immediate treatment initiation). The primary outcome was treatment completion, defined as dispensing the final package of the prescribed treatment within six months after enrolment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 200 HCV RNA positive individuals were enrolled between 1 October 2019 and 31 December 2021 (mean age 47.4 years, 72.5% male, 60.5% injected past 3 months, 20.4% cirrhosis). Treatment completion was accomplished by 67 of 98 (68.4% [95% confidence interval {CI}: 58.2\u201377.4]) during intervention conditions and by 36 of 102 (35.3% [95% CI: 26.1\u201345.4]) during control conditions (risk difference 33.1% [95% CI: 20.0\u201346.2]; risk ratio 1.9 [95% CI: 1.4\u20132.6]). The intervention was superior in terms of treatment completion (adjusted odds ratio [aOR] 4.8 [95% CI: 1.8\u201312.8]; P = .002) and time to treatment initiation (adjusted hazard ratio [aHR] 4.0 [95% CI: 2.5\u20136.3]; P &amp;lt; .001). Sustained virologic response was documented in 60 of 98 (61.2% [95% CI: 50.8\u201370.9]) during intervention and in 66 of 102 (64.7% [95% CI: 54.6\u201373.9]) during control conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An opportunistic test-and-treat approach to HCV infection was superior to standard of care among hospitalized PWID. The model of care should be considered for broader implementation.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. NCT04220645<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciad711","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:45:52Z","timestamp":1700243152000},"page":"582-590","source":"Crossref","is-referenced-by-count":28,"title":["Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-5107","authenticated-orcid":false,"given":"H\u00e5vard","family":"Midgard","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Oslo University Hospital , Oslo , Norway"},{"name":"Department of Infectious Diseases, Akershus University Hospital , L\u00f8renskog , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Braathen","family":"Malme","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Akershus University Hospital , L\u00f8renskog , Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Meinich","family":"Pihl","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lovisenberg Diaconal Hospital , Oslo , Norway"},{"name":"Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka Mari","family":"Berg-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Tanum","sequence":"additional","affiliation":[{"name":"Department for Research and Development in Mental Health, Akershus University Hospital , L\u00f8renskog , Norway"},{"name":"Faculty of Health Sciences, Oslo Metropolitan University , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Klundby","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Haug","sequence":"additional","affiliation":[{"name":"Department of Acute Medicine, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Tveter","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Bj\u00f8rnestad","sequence":"additional","affiliation":[{"name":"ProLAR Nett , S\u00f8gne , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Christoffer","family":"Olsen","sequence":"additional","affiliation":[{"name":"Department of Research Support for Clinical Trials, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane-Kristine","family":"Finbr\u00e5ten","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lovisenberg Diaconal Hospital , Oslo , Norway"},{"name":"Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Dalgard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Akershus University Hospital , L\u00f8renskog , Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"2024032020255209900_ciad711-B1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","article-title":"Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013","volume":"16","author":"Degenhardt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024032020255209900_ciad711-B2","author":"World Health Organization"},{"key":"2024032020255209900_ciad711-B3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024032020255209900_ciad711-B4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"2024032020255209900_ciad711-B5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugpo.2018.10.004","article-title":"Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy","volume":"62","author":"Grebely","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2024032020255209900_ciad711-B6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024032020255209900_ciad711-B7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann Intern Med"},{"key":"2024032020255209900_ciad711-B8","doi-asserted-by":"crossref","first-page":"e1003653","DOI":"10.1371\/journal.pmed.1003653","article-title":"Integrated treatment of hepatitis C virus infection among people who inject drugs: a multicenter randomized controlled trial (INTRO-HCV)","volume":"18","author":"Fadnes","year":"2021","journal-title":"PLoS Med"},{"key":"2024032020255209900_ciad711-B9","doi-asserted-by":"crossref","first-page":"103165","DOI":"10.1016\/j.drugpo.2021.103165","article-title":"Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway","volume":"96","author":"Midgard","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2024032020255209900_ciad711-B10","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/liv.14227","article-title":"The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals","volume":"39","author":"Bartlett","year":"2019","journal-title":"Liver Int"},{"key":"2024032020255209900_ciad711-B11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2020.08.038","article-title":"High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia","volume":"74","author":"Valerio","year":"2021","journal-title":"J Hepatol"},{"key":"2024032020255209900_ciad711-B12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.13949","article-title":"Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework","volume":"39","author":"Day","year":"2019","journal-title":"Liver Int"},{"key":"2024032020255209900_ciad711-B13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jvh.12153","article-title":"Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's hepatitis C Action Plan","volume":"21","author":"McDonald","year":"2014","journal-title":"J Viral Hepat"},{"key":"2024032020255209900_ciad711-B14","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/cid\/ciz546","article-title":"Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs","volume":"70","author":"Wade","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024032020255209900_ciad711-B15","doi-asserted-by":"crossref","first-page":"109543","DOI":"10.1016\/j.drugalcdep.2022.109543","article-title":"Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study","volume":"237","author":"Wheeler","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"2024032020255209900_ciad711-B16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1017\/S0950268814000284","article-title":"Healthcare seeking and hospital admissions by people who inject drugs in response to symptoms of injection site infections or injuries in three urban areas of England","volume":"143","author":"Hope","year":"2015","journal-title":"Epidemiol Infect"},{"key":"2024032020255209900_ciad711-B17","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/cid\/ciab526","article-title":"Opportunities to enhance linkage to hepatitis C care among hospitalized people with recent drug dependence in New South Wales, Australia: a population-based linkage study","volume":"73","author":"Valerio","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024032020255209900_ciad711-B18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/jvh.12548","article-title":"Higher all-cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study (CHeCS), 2006\u20132013","volume":"23","author":"Teshale","year":"2016","journal-title":"J Viral Hepat"},{"key":"2024032020255209900_ciad711-B19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drugpo.2018.11.003","article-title":"Opportunistic assessment and treatment of people with hepatitis C virus infection admitted to hospital for other reasons: a prospective cohort study","volume":"65","author":"Chiong","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2024032020255209900_ciad711-B20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08897077.2021.1932699","article-title":"Exploring how hospitalization can alter hepatitis C virus treatment prioritization and trajectories in people who use drugs: a qualitative analysis","volume":"43","author":"Levander","year":"2022","journal-title":"Subst Abus"},{"key":"2024032020255209900_ciad711-B21","doi-asserted-by":"crossref","first-page":"h391","DOI":"10.1136\/bmj.h391","article-title":"The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting","volume":"350","author":"Hemming","year":"2015","journal-title":"BMJ"},{"key":"2024032020255209900_ciad711-B22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s13063-020-04434-8","article-title":"Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs","volume":"21","author":"Midgard","year":"2020","journal-title":"Trials"},{"key":"2024032020255209900_ciad711-B23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13063-017-1833-7","article-title":"Analysis of cluster randomised stepped wedge trials with repeated cross-sectional samples","volume":"18","author":"Hemming","year":"2017","journal-title":"Trials"},{"key":"2024032020255209900_ciad711-B24","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the Cox model","author":"Therneau","year":"2000"},{"key":"2024032020255209900_ciad711-B25","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/sim.7329","article-title":"The use of permutation tests for the analysis of parallel and stepped-wedge cluster-randomized trials","volume":"36","author":"Wang","year":"2017","journal-title":"Stat Med"},{"key":"2024032020255209900_ciad711-B26","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"2024032020255209900_ciad711-B27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/1536867X1401400208","article-title":"A menu-driven facility for power and detectable-difference calculations in Stepped-Wedge Cluster-Randomized Trials","volume":"2","author":"Hemming","year":"2014","journal-title":"Stata J 14"},{"key":"2024032020255209900_ciad711-B28","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/liv.15266","article-title":"Peer support in small towns: a decentralized mobile hepatitis C virus clinic for people who inject drugs","volume":"42","author":"Midgard","year":"2022","journal-title":"Liver Int"},{"key":"2024032020255209900_ciad711-B29","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","article-title":"Patient-centered models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial","volume":"7","author":"Litwin","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024032020255209900_ciad711-B30","article-title":"Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs","volume":"In Press","author":"Opheim","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2024032020255209900_ciad711-B31","doi-asserted-by":"crossref","first-page":"103135","DOI":"10.1016\/j.drugpo.2021.103135","article-title":"High HCV cure rates among people who inject drugs and have suboptimal adherence: a patient-centered approach to HCV models of care","volume":"93","author":"Norton","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2024032020255209900_ciad711-B32","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2017.11.031","article-title":"Four weeks of ledipasvir\/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial","volume":"68","author":"Ovrehus","year":"2018","journal-title":"J Hepatol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad711\/54142795\/ciad711.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/3\/582\/57037611\/ciad711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/3\/582\/57037611\/ciad711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T16:26:23Z","timestamp":1710951983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/3\/582\/7441960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,11,22]]},"published-print":{"date-parts":[[2024,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad711","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,15]]},"published":{"date-parts":[[2023,11,22]]}}}